Table 5.

Interaction between MSCs and hematologic neoplasms by microvesicles transferring

Type of malignancy/cell (source)	Target	Content	Results	References
MDS-MSCs	CD34+ cells	miR-10a and miR-15a	Modifying CD34+ cell viability, CFU-GM production, MDM2 and P53 genes expression	[99]
CML cell line LAMA84	Human vascular endothelial cells	Different biomolecules	Upregulation of ICAM‐1, VCAM‐1 and IL‐8, pro-angiogenic pattern	[104]
MM	MSCs	Osteoclast activating factors	Osteoclast differentiation, osteoclast bone resorption activity	[105]
MM	MSCs	miR-21 and miR-146a	MM cell growth, survival and proliferation, CAF transformation, IL-6 secretion of MSCs	[115]
B-CLL	Leukemia B cells	CCL3/4, EGR1/2/3, and MYC	Escaping from spontaneous or drug-induced apoptosis, migrating in higher rate and modifying genes more suitably	[106]
MSCs	Microenvironment	IL-6 and IL-8	Hematopoiesis inhibition by downregulating the CXCL12, angiopoietin 1, and kit ligand	[71]
MSC cell line HS5	CML cell line LAMA84	IL-8	Survival, proliferation, migration	[71]
K562	BM-MSCs	miR-711	Suppressed adhesion abilities of BM-MSCs	[107]
MSCs	AML cell line	miR-222-3p	IRF2/INPP4B signaling inhibition	[108]
MSCs	AML cell line	TGF-β1, miR-155, and miR-375	AML cell resistance to tyrosine kinase inhibitors	[111]
AML	MSCs	miR-150	Disruption of the CXCR4/ CXCL12 axis	[111]
AML cell lines; HEL 92.1.7, HL-60, MOLM-14, and U937	MSCs	mRNA of IGF1R, MMP-9, NPM1, CXCR4, FLT3 FLT3-ITD	Leukemia progression	[71]
MM-MSC	MM	IL-6, CCL2 Fibronectin	↓ miR-15a content in MM-MSCs, induces tumor growth and promotes myeloma dissemination	[71, 113, 114]
ATL	MSCs	Tax viral oncoprotein of HTLV-I	↓ MSC stemness and improved angiogenesis	[71]
CML	MSCs	IL-8	IL-8 secretion, CML cell survival	[112]
CLL	MSCs	Protein and miRNA	Creation of leukemia-surviving subpopulation of MSCs	[117]